Corporate digest
Add BT as a preferred sourceLonza Group
CHEMICALS and biotech company Lonza Group will buy a sterile drug product fill-and-finish facility in Stein, Switzerland, from Novartis. Lonza, which has a secondary listing on the Singapore Exchange, said it had entered into a binding contractual commitment for the acquisition, but did not disclose the purchase price.
It will use the facility to manufacture drug products for Novartis, as well as to provide production capacity for its additional customers.
TRENDING NOW
When every phone becomes a satellite phone, what happens to Asia’s telcos?
Lily Ler to step down as CEO of Mapletree Industrial Trust manager
Jardine C&C selling Singapore, Malaysia dealerships to Indonesia’s Chandra Asri for US$221 million gain
Digital Realty, STT GDC among data centre operators awarded 50 MW of new capacity in Singapore
